1 / 9

Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria

CHVI/CIDA. GHRI/CHVI/CIDA/IDRC /CIHR. Afri -Can Synchronicity Forum 17-19 Jan. 2012, Entebbe. Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator.

charis
Télécharger la présentation

Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHVI/CIDA GHRI/CHVI/CIDA/IDRC/CIHR • Afri-Can Synchronicity Forum 17-19 Jan. 2012, Entebbe Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples Cohort Is Still Relevant For HIV Vaccine Studies Despite Low Transmission Rates; Canadian–Nigerian Experience

  2. Background GHRI/CHVI/CIDA/IDRC/CIHR Discordant couples have been known to be medium risk group for HIV transmission. This group is suitable for HIV vaccine trials due to: • the natural exposure • high retention rates recorded in the past. A cohort of HIV sero-negative volunteers of discordant couples has been developed in Nigeria to record : behavioral data, risk factors, HIV incidence, STI infections, and retention rates.

  3. Study flow GHRI/CHVI/CIDA/IDRC/CIHR *Counseling *Referrals (community) Screening (Eligibility criteria) No Eligible? Sero-discordance STOP Yes Consent & Enroll • ● Behavioral data ●Medical history/exams ●Serology tests ●Safety Labs Medical examination and labs supporting HIV+ partners 11 study visits (2 years FU) Complete

  4. Methods GHRI/CHVI/CIDA/IDRC/CIHR Laboratory: HIV negative • Serology tests • Safety Labs- CBC, LFT and KFT Clinical: • Medical History and Examinations • Referrals to appropriate clinics HIV positive partners- • CD4 counts (PartecCyflow SL3 counter) • Viral Loads (ROCHE COBAS Taqman 96; HIV v2.0)

  5. Results- Risk Factors GHRI/CHVI/CIDA/IDRC/CIHR

  6. Results- Risk factors (HIV+ partners) GHRI/CHVI/CIDA/IDRC/CIHR HIV incidence : The recorded incidence in this cohort is 0.6%

  7. Conclusion GHRI/CHVI/CIDA/IDRC/CIHR • Despite antiretroviral treatment, sero- negative partners are still at risk of getting infected mainly due to: • Inconsistent and lack of condom use. • A high percentage of sero-positive partners still have detectable viral loads. • Prevailing STIs among HIV negative and HIV positive partners • Sero-discordant couple cohort remains an important natural adult model for transmission studies; and • ..presents an opportunity to test vaccines in HIV exposed adults

  8. Acknowledgements GHRI/CHVI/CIDA/IDRC/CIHR This work was carried out with support from the Global Health Research Initiative (GHRI), a research funding partnership composed of the Canadian Institutes of Health Research, the Canadian International Development Agency, and the International Development Research Centre. • PLASVIREC’s Research team: Counseling, Clinical, Data & Lab team • All the discordant couples that volunteered for this study • Dr. Pam Datong • Dr. EvaeziOkpokoro • Dr. Alash’le Abimiku

  9. GHRI/CHVI/CIDA/IDRC/CIHR

More Related